Loading...
XNAS
RGEN
Market cap8.12bUSD
Jul 10, Last price  
144.24USD
1D
4.75%
1Q
19.85%
Jan 2017
367.03%
Name

Repligen Corp

Chart & Performance

D1W1MN
XNAS:RGEN chart
P/E
166.41
P/S
11.02
EPS
0.87
Div Yield, %
Shrs. gr., 5y
0.97%
Rev. gr., 5y
15.05%
Revenues
738m
+16.36%
12,911,40414,074,23919,296,28129,361,52120,971,06927,291,02462,266,53668,169,62363,548,34983,537,000104,541,000141,236,000194,032,000270,245,000366,260,000670,534,000801,536,000632,362,000634,439,000738,256,000
Net income
49m
P
696,860-889,26337,106,5145,746,028-4,063,844-43,50914,156,03716,093,1558,170,2149,345,00011,681,00028,353,00016,617,00021,411,00059,926,000128,291,000185,959,00035,596,000-25,514,00048,894,000
CFO
117m
-33.06%
415,384405,48238,466,6016,307,144-2,448,3543,231,76313,439,60825,929,96718,401,29815,053,0007,521,00017,451,00032,770,00067,216,00062,625,000119,016,000172,083,000113,918,000175,394,000117,417,000

Notes

No notes on this company yet
Write a private note on this company, for your eyes only

Profile

Repligen Corporation specializes in the creation and distribution of advanced bioprocessing technologies and integrated systems. These solutions are vital for various stages of biological drug production, serving clients across North America, Europe, the Asia Pacific region, and other international markets. The company's diverse product portfolio includes crucial components for biomanufacturing. This encompasses Protein A ligands, which serve as the key binding elements within Protein A affinity chromatography resins, as well as specialized cell culture growth factors. In the realm of chromatography, Repligen offers a range of products: Its OPUS line features pre-packed chromatography columns, instrumental in purifying biologics, alongside smaller-scale OPUS columns designed for high-throughput process development screening, viral clearance validation studies, and the scaling-down of chromatography processes. Additionally, the company supplies ELISA test kits and chromatography resins marketed under the CaptivA brand. Repligen also boasts an extensive suite of filtration products. This includes XCell Alternating Tangential Flow systems, which are filtration devices utilized in upstream perfusion and cell culture processing. For downstream applications like biologic drug concentration and formulation, they provide TangenX flat sheet cassettes. Other filtration offerings encompass KrosFlo tangential flow filtration and tangential flow depth filtration systems, Spectra/Por laboratory and process dialysis products, SpectraFlo dynamic dialysis systems, and ProConnex single-use hollow fibers. Furthermore, Repligen addresses process analytics with its slope spectroscopy systems, branded as SoloVPE, FlowVPE, and FlowVPX. Their clientele is broad, consisting of life sciences organizations, biopharmaceutical and diagnostics companies, laboratory researchers, and contract manufacturing organizations. Repligen also collaborates with partners, such as Navigo Proteins GmbH, on the development of various affinity ligands. The corporation was founded in 1981 and maintains its corporate headquarters in Waltham, Massachusetts.
IPO date
Apr 29, 1986
Employees
2,025
Domiciled in
US
Incorporated in
US

Valuation

Title
USD in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2025‑122024‑122023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑12
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT